Compounded copies of GLP-1 drugs like semaglutide and tirzepatide are being phased out now that regulators no longer consider the branded drugs in shortage. Hundreds of thousands of patients who relied on cheaper compounded versions at around $200 per month must find alternatives, but even discounted brand prices of $350-$700 monthly remain unaffordable for many. Telehealth companies and compounding pharmacies are pursuing risky strategies like changing prescriptions or encouraging stockpiling. Experts describe the situation as a 'lose-lose' for patients.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.